Clinical Utility of Molecular Testing of All Colorectal Cancer Cases as a Standing Colon Cancer Panel Order for Selection of Patients for Targeted Therapies

Kongkamka S.; Oberstein P. E.; Hsiao S.; Turk A. T.; Sired A. N.; Kurtis B. M.; Varma H.; Neugut A. I.; Mansukhani M.; Sepulveda A. R.

首页> 外文期刊>The Journal of molecular diagnostics: JMD >Clinical Utility of Molecular Testing of All Colorectal Cancer Cases as a Standing Colon Cancer Panel Order for Selection of Patients for Targeted Therapies

【24h】

Clinical Utility of Molecular Testing of All Colorectal Cancer Cases as a Standing Colon Cancer Panel Order for Selection of Patients for Targeted Therapies

机译：所有结肠直肠癌病例的分子检测作为结肠癌常规检查标准的临床效用，可用于选择靶向治疗的患者

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of molecular diagnostics: JMD》 |2016年第6期|共2页
作者
Kongkamka S.; Oberstein P. E.; Hsiao S.; Turk A. T.; Sired A. N.; Kurtis B. M.; Varma H.; Neugut A. I.; Mansukhani M.; Sepulveda A. R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类临床医学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical Utility of Molecular Testing of All Colorectal Cancer Cases as a Standing Colon Cancer Panel Order for Selection of Patients for Targeted Therapies [J] . Kongkamka S., Oberstein P. E., Hsiao S., The Journal of molecular diagnostics: JMD . 2016,第6期

机译：所有结肠直肠癌病例的分子检测作为结肠癌常规检查标准的临床效用，可用于选择靶向治疗的患者
2. Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing [J] . Lorans Marie, Dow Eryn, Macrae Finlay A., Clinical colorectal cancer . 2018,第2期

机译：遗传结直肠癌的更新：改善多烯面板测试的临床效用
3. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. [J] . Loupakis F, Bocci G, Pasqualetti G, Current cancer drug targets . 2010,第1期

机译：在转移性结直肠癌的一线治疗中靶向血管内皮生长因子途径：患者临床和分子选择的最新和未来观点。
4. A Vision for the Development of Molecularly Targeted Therapies for Colon Cancer in 2012 [C] . James H. Doroshow Gastrointestinal Cancers Symposium . 2012

机译：2012年结肠癌分子靶向治疗的愿景
5. Universal Screening for Familial Colorectal Cancer Syndromes at Seattle Cancer Care Alliance: Qualitative Study of Providers involved in Implementation and Patients Experience with First Wave of Testing [D] . Hyams, Travis. 2016

机译：西雅图癌症护理联盟对家族性结直肠癌综合征的通用筛查：参与实施的提供者的定性研究和第一波测试的患者经验
6. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline [O] . Natasha B. Leighl, Natasha Rekhtman, William A. Biermann, -1

机译：为表皮生长因子受体和间变性淋巴瘤激酶酪氨酸激酶抑制剂选择肺癌患者的分子检测：美国病理学家学院/国际肺癌研究协会/分子病理学协会国际临床病理学会认可
7. Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel [O] . J.F. Seligmann, F. Elliott, S. Richman, 2020

机译：先进的右旋环，左旋塞和直肠癌的临床和分子特征及治疗结果：来自1180名患者的胰腺炎患者的数据，延伸生物标志物面板

Clinical Utility of Molecular Testing of All Colorectal Cancer Cases as a Standing Colon Cancer Panel Order for Selection of Patients for Targeted Therapies

著录项

相似文献

相关主题

期刊订阅